Mig Sleeper, vice president, Global Pricing for Astellas Pharma Europe, explains why we must rethink how value is defined as we enter a new technological era for medicines.
Software that can be used to monitor patients with neurodegenerative disorder amyotrophic lateral sclerosis (ALS) using their voice patterns has been granted breakthrough